BioRegenx, Inc.
BRGX
$0.01
$0.000.00%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 426.20K | 385.60K | 507.80K | 446.00K | 515.10K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 426.20K | 385.60K | 507.80K | 446.00K | 515.10K |
| Cost of Revenue | 77.90K | 66.90K | 81.40K | 93.50K | 109.10K |
| Gross Profit | 348.30K | 318.80K | 426.40K | 352.50K | 406.00K |
| SG&A Expenses | 398.10K | 554.40K | 434.90K | 459.70K | 598.60K |
| Depreciation & Amortization | -- | -25.00K | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 475.90K | 596.30K | 516.20K | 553.20K | 707.80K |
| Operating Income | -49.80K | -210.70K | -8.50K | -107.30K | -192.60K |
| Income Before Tax | -26.40K | -1.02M | -80.60K | -178.30K | -266.90K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -26.40K | -1.02M | -80.60K | -178.30K | -266.90K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -26.40K | -1.02M | -80.60K | -178.30K | -266.90K |
| EBIT | -49.80K | -210.70K | -8.50K | -107.30K | -192.60K |
| EBITDA | -36.80K | -172.70K | 3.90K | -69.90K | -180.20K |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 969.17M | 961.68M | 960.87M | 959.21M | 956.99M |
| Average Diluted Shares Outstanding | 969.17M | 961.68M | 960.87M | 959.21M | 956.99M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |